About Gap junction beta-1 protein
Gap junction beta-1 protein (GJB1) is a protein
from Homo sapiens identified by UniProt accession
P08034, 283 residues long.
MolForge cross-references it against 0 known binders and
259 disease associations.
Target properties
| Protein name | Gap junction beta-1 protein |
|---|
| UniProt accession | P08034 |
|---|
| Gene | GJB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 283 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (259)
Diseases linked to this target (Open Targets).
- X-linked Charcot-Marie-Tooth disease type 1 · score 0.85
- Charcot-Marie-Tooth disease X-linked dominant 1 · score 0.85
- Charcot-Marie-Tooth disease · score 0.56
- genetic disorder · score 0.54
- peripheral neuropathy · score 0.53
- Charcot-Marie-Tooth disease type 3 · score 0.44
- Dejerine-Sottas syndrome · score 0.44
- hereditary motor and sensory neuropathy · score 0.40
- neuropathy · score 0.40
- X-linked progressive cerebellar ataxia · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P08034-F1 | alphafold | PREDICTED | 80.23 | — |
Amino-acid sequence (283 residues)
MNWTGLYTLL SGVNRHSTAI GRVWLSVIFI FRIMVLVVAA ESVWGDEKSS FICNTLQPGC NSVCYDQFFP ISHVRLWSLQ LILVSTPALL VAMHVAHQQH IEKKMLRLEG HGDPLHLEEV KRHKVHISGT LWWTYVISVV FRLLFEAVFM YVFYLLYPGY AMVRLVKCDV YPCPNTVDCF VSRPTEKTVF TVFMLAASGI CIILNVAEVV YLIIRACARR AQRRSNPPSR KGSGFGHRLS PEYKQNEINK LLSEQDGSLK DILRRSPGTG AGLAEKSDRC SAC
Explore Gap junction beta-1 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets